The role of reactive oxygen species (ROS) in the effector mechanisms of human antimycobacterial immunity

Biochemistry and Molecular Biology International

Volumn 43, Issue 2, 1997, Pages 399-408

  Fazal, Nadeem ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Chronic Granulomatous Disease; Fazal's microcolony counting method; IFN ; Macrophages; Mycobacteria; Neutrophils; TNF

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; OXYGEN RADICAL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CELL TYPE; CHRONIC GRANULOMATOUS DISEASE; COLONY FORMING UNIT; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MACROPHAGE; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; NEUTROPHIL; PHAGOCYTE;

ACTINOBACTERIA (CLASS); BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; UNCULTURED ACTINOMYCETE;

EID: 0031401809     PISSN: 10399712     EISSN: None     Source Type: Journal    
DOI: 10.1080/15216549700204191     Document Type: Article

References (30)

1. Hasset JD, Cohen MS. FASED J 1989;3:2574-2582.
2. Bloch H. Am Rev Tuberculosis 1948;58;667-70
3. Montgomery LJ, Lemon W. J Thorac Cardiovasc Surgery 1933; 2;429-38.
4. Antony VB, Sahn SA, Harada RN. Chest 1983;83 (suppl):95-96.
5. Curnutte JT, Babior BM. Adv Human Genet 1987;16;229-298.
6. Jones GS, Amirault HJ, Anderson BR. J Infect Dis 1990;162;700-704.
7. Brown AE, Holzer TJ, Anderson BR. (1987), J Infect Dis 1987;156; 985-989.
8. Fazal N, Lammas DA, Pithie AS, Rahelu M, Gaston JSH, Kumararatne DS. Clinical & Experimental Immunology 1995;99;82-89.
9. Pithie AD, Lammas DA, Fazal N, Rahelu M, Bartlett R, Gaston JSH, Kumararatne DS. FEMS Immunology & Medical Microbiology 1995;11, 145-154.
10. Fazal N, Bartlett R, Lammas DA, Kumararatne DS. FEMS Immunology & Microbiology, 1992;105:355-362.
11. Fazal N, Bartlett R, Lammas DA, Raykundalia C, Kumararatne DS. FEMS Immunology & Microbiology, 1992;105:337-346.
12. Denis M. J Infec Dis 1991;163:919.
13. Anderson AB. J Infect Dis 1991;156:985-989.
14. Sechler JMG, Malech HL, White CJ. Proc Natl Acad Sci 1977;85:4874-8
15. Denaver MC. Interferon and CGD: Current opinion in Immunology 1991;3:61-64
16. Johnston RB, NEJM, 1984;310:1237-43
17. Marshall BG, Chambers MA, Wangoo A, Shaw RJ, Young DB, Infect. Immun 1997, 65, No. 5: 1931-1935.
18. Chan J, Tanaka D, Carrol J, et al, Infect. Immun 1995, 63:736-40
19. Rook GAW, Steele J, Ainsworth M, Champion BR. Clin. Exp. Immunol. 1986; 59:333-338.
20. Crowle AJ. Res Microbiology 1990;141;231-236
21. Flesch IEA, Kaufmann SHE. Infect Immun 1990;58;2675-77
22. Walker L, Lowrie DB. Nature 1981; 293;69-70.
23. Kaufmann SHE. Ann Rev Immunol 1993;11;129-63.
24. Rook GAW, Steele J, Ainsworth M, Champion BR. Immunology 1986;59: 333-338.
25. Douvas GS, Looker DL, Vatter AE, Crowle AJ. Infect Immun 1985;50;1-8.
26. Rook GAW, Al Attiyah RJ. Tubercle 1990;72;768-770.
27. Havell EA. J Infec Dis 1986;153:690
28. Appleburg R , Orme IM, Desouza MIP, Silva MT. Immunology 1992;76: 553-559.
29. Bermudez LE. J Immunol 1993;150:1838-1845
30. Barker K, Hongxia F, Clare C, Kaplan G, Barker J, Wilhelmine JH, Cohn Z A. Infect Immun 1996; 64:2, 428-433.